Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Epcoritamab Consolidation Post CAR T in LBCL (EpLCART)
NCT06414148Phase 2Recruiting
- Sponsor
- Peter MacCallum Cancer Centre
- Start
- May 2024
- Primary completion
- Oct 2026
- Modality
- Antibody Conjugates, Bispecific Antibodies, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of epcoritamab in diffuse large B-cell lymphoma (DLBCL), sponsored by Peter MacCallum Cancer Centre. Started May 2024; status: recruiting.
02
Drugs
epcoritamab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT06414148.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06414148.